Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

17,215 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon-Small-Cell Lung Cancer With EGFR Exon 19 Deletion or L858R Mutations.
Lu S, Dong X, Jian H, Chen J, Chen G, Sun Y, Ji Y, Wang Z, Shi J, Lu J, Chen S, Lv D, Zhang G, Liu C, Li J, Yu X, Lin Z, Yu Z, Wang Z, Cui J, Xu X, Fang J, Feng J, Xu Z, Ma R, Hu J, Yang N, Zhou X, Wu X, Hu C, Zhang Z, Lu Y, Hu Y, Jiang L, Wang Q, Guo R, Zhou J, Li B, Hu C, Tong W, Zhang H, Ma L, Chen Y, Jie Z, Yao Y, Zhang L, Jie W, Li W, Xiong J, Ye X, Duan J, Yang H, Sun M, Sun C, Wei H, Li C, Ali SM, Miller VA, Wu Q. Lu S, et al. Among authors: hu c, hu j, hu y. J Clin Oncol. 2022 Sep 20;40(27):3162-3171. doi: 10.1200/JCO.21.02641. Epub 2022 May 17. J Clin Oncol. 2022. PMID: 35580297 Free PMC article. Clinical Trial.
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study.
Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, Zhang S, Wang J, Zhou S, Ren S, Lu S, Zhang L, Hu C, Hu C, Luo Y, Chen L, Ye M, Huang J, Zhi X, Zhang Y, Xiu Q, Ma J, Zhang L, You C. Zhou C, et al. Among authors: hu c. Lancet Oncol. 2011 Aug;12(8):735-42. doi: 10.1016/S1470-2045(11)70184-X. Epub 2011 Jul 23. Lancet Oncol. 2011. PMID: 21783417 Clinical Trial.
[Efficacy and toxicity of pemetrexed or gemcitabine combined with cisplatin in the treatment of patients with advanced non-small cell lung cancer].
Hu X, Jiao S, Zhang S, Wang Z, Wang M, Huang C, Zheng R, Li K, Wang J, Wang Y, Ouyang X, Lv W, Cheng G, Hu C, Luo R, Sun Y. Hu X, et al. Among authors: hu c. Zhongguo Fei Ai Za Zhi. 2012 Oct;15(10):569-75. doi: 10.3779/j.issn.1009-3419.2012.10.02. Zhongguo Fei Ai Za Zhi. 2012. PMID: 23075680 Free PMC article. Clinical Trial. Chinese.
[A phase II prospective randomized controlled trial of weekly paclitaxel combined with S-1 or fluorouracil for advanced gastric carcinoma].
Huang DZ, Xiong JP, Xu N, Yan Z, Zhuang ZX, Yu Z, Wan HP, Zhang Y, Deng T, Zheng RS, Guo ZQ, Hu CH, Wang ML, Yu ZH, Yao Y, Meng JC, Ba Y. Huang DZ, et al. Zhonghua Zhong Liu Za Zhi. 2012 Nov;34(11):865-8. doi: 10.3760/cma.j.issn.0253-3766.2012.11.015. Zhonghua Zhong Liu Za Zhi. 2012. PMID: 23291139 Clinical Trial. Chinese.
Safety analysis of weekly paclitaxel plus S-1 versus paclitaxel plus 5-fluorouracil/calcium folinate as first-line therapy in advanced gastric cancer: a multicenter open random phase II trial.
Deng T, Xu N, Xiong JP, Yan Z, Zhuang ZX, Yu Z, Wan HP, Zhang Y, Huang DZ, Zheng RS, Guo ZQ, Hu CH, Wang ML, Yu ZH, Yao Y, Meng JC, Ba Y. Deng T, et al. J Chemother. 2013 Feb;25(1):56-9. doi: 10.1179/1973947812Y.0000000057. J Chemother. 2013. PMID: 23433446 Clinical Trial.
Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial.
Shi Y, Zhang L, Liu X, Zhou C, Zhang L, Zhang S, Wang D, Li Q, Qin S, Hu C, Zhang Y, Chen J, Cheng Y, Feng J, Zhang H, Song Y, Wu YL, Xu N, Zhou J, Luo R, Bai C, Jin Y, Liu W, Wei Z, Tan F, Wang Y, Ding L, Dai H, Jiao S, Wang J, Liang L, Zhang W, Sun Y. Shi Y, et al. Among authors: hu c. Lancet Oncol. 2013 Sep;14(10):953-61. doi: 10.1016/S1470-2045(13)70355-3. Epub 2013 Aug 13. Lancet Oncol. 2013. PMID: 23948351 Clinical Trial.
Platinum-based chemotherapy plus cetuximab first-line for Asian patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: Results of an open-label, single-arm, multicenter trial.
Guo Y, Shi M, Yang A, Feng J, Zhu X, Choi YJ, Hu G, Pan J, Hu C, Luo R, Zhang Y, Zhou L, Cheng Y, Lüpfert C, Cai J, Shi Y. Guo Y, et al. Among authors: hu c, hu g. Head Neck. 2015 Aug;37(8):1081-7. doi: 10.1002/hed.23707. Epub 2014 Sep 17. Head Neck. 2015. PMID: 24710768 Free article. Clinical Trial.
A multicenter, open-label, randomized phase II controlled study of rh-endostatin (Endostar) in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer.
Lu S, Li L, Luo Y, Zhang L, Wu G, Chen Z, Huang C, Guo S, Zhang Y, Song X, Yu Y, Zhou C, Li W, Liao M, Li B, Xu L, Chen P, Hu C, Hu C. Lu S, et al. Among authors: hu c. J Thorac Oncol. 2015 Jan;10(1):206-11. doi: 10.1097/JTO.0000000000000343. J Thorac Oncol. 2015. PMID: 25654728 Free article. Clinical Trial.
17,215 results
You have reached the last available page of results. Please see the User Guide for more information.